Viking Therapeutics Inc (NASDAQ:VKTX) received a $5.00 price objective from analysts at Maxim Group in a report issued on Friday. The firm currently has a a “buy” rating on the stock. Maxim Group’s price target points to a potential upside of 331.03% from the stock’s previous close.

VKTX has been the subject of a number of other reports. Laidlaw decreased their price target on Viking Therapeutics from $20.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, August 11th. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Viking Therapeutics in a research report on Sunday, September 18th.

Viking Therapeutics (NASDAQ:VKTX) opened at 1.16 on Friday. The stock’s 50 day moving average price is $1.17 and its 200-day moving average price is $1.27. The firm’s market cap is $22.36 million. Viking Therapeutics has a 12-month low of $0.94 and a 12-month high of $5.17.

Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings results on Thursday, November 10th. The company reported ($0.20) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.01. Equities research analysts anticipate that Viking Therapeutics will post ($0.98) earnings per share for the current fiscal year.

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

5 Day Chart for NASDAQ:VKTX

Receive News & Stock Ratings for Viking Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc and related stocks with our FREE daily email newsletter.